Clinical Edge Journal Scan

Dietary iron protects against gastric cancer


 

Key clinical point: Dietary iron shows an inverse association with the risk for gastric cancer irrespective of cancer subsite and histological type.

Major finding: Dietary iron intake was inversely associated with the risk for gastric cancer (per quartile odds ratio [OR] 0.88; 95% CI 0.83-0.93). The association (per quartile) was significant for cardia (OR 0.85; 95% CI 0.77-0.94) and noncardia (OR 0.87; 95% CI 0.81-0.94) gastric cancer and diffuse (OR,0.79; 95% CI 0.69-0.89) and intestinal (OR 0.88; 95% CI 0.79-0.98) type.

Study details: An analysis of pooled data from 11 case-control studies including 4658 participants with gastric cancer and 12,247 control participants from the Stomach Cancer Pooling Project.

Disclosures: This study was supported by AIRC Foundation for Cancer Research, Italy. The authors declared no conflicts of interest.

Source: Collatuzzo G et al. Inverse association between dietary iron intake and gastric cancer: A pooled analysis of case-control studies of the stop consortium. Nutrients. 2022;14(12):2555 (Jun 20). Doi: 10.3390/nu14122555

Recommended Reading

CRC: Colonoscopy offers a survival benefit over fecal immunochemical test
MDedge Hematology and Oncology
Cardiovascular disease: The leading cause of noncancer death in CRC
MDedge Hematology and Oncology
Hepatic arterial infusion-chemotherapy with FOLFIRINOX: A feasible treatment option for metastatic CRC
MDedge Hematology and Oncology
Beta adrenergic blockade improves the prognosis of patients with CRC
MDedge Hematology and Oncology
Advanced gastric cancer: Efficacy of anti-PD-1 antibodies plus multikinase inhibitors unaffected by liver metastasis
MDedge Hematology and Oncology
Chemoradiotherapy improves survival in resectable gastric cancer
MDedge Hematology and Oncology
Better survival in patients with MSI-high vs MSS gastric cancer despite worse chemotherapy response
MDedge Hematology and Oncology
Hyperglycemia and low BMI increase the risk for gastric cancer
MDedge Hematology and Oncology
Gastric cancer: Neoadjuvant chemotherapy improves outcomes
MDedge Hematology and Oncology
Cisplatin not inferior to oxaliplatin for systemic treatment of resectable GC
MDedge Hematology and Oncology